Key result
Edoxaban 60/30 mg once daily significantly reduced the risk of stroke or systemic embolism compared to warfarin (HR 0.79, p=0.02 for superiority) in patients with non-valvular atrial fibrillation.
Why the study?
To address important practical aspects of using edoxaban in patients with nonvalvular atrial fibrillation based on the results of the ENGAGE AF-TIMI 48 trial.
Does edoxaban improve efficacy and safety compared to warfarin in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Edoxaban vs warfarin
Design
Review of a prospective, randomized, double-blind, placebo-controlled trial
Authors
Loading...
Provides practical edoxaban guidance in nonvalvular AF; leaves open need for updated real-world validation.
Does edoxaban improve efficacy and safety compared to warfarin in patients with nonvalvular atrial fibrillation?
Hazard Ratio: 0.79 (95% CI 0.63–0.99)
Absolute Event Rate: 1.18% vs 1.5%
p-value: p=<0.001 for noninferiority; 0.02 for superiority
This review discusses the practical aspects of using edoxaban for stroke prevention in patients with nonvalvular atrial fibrillation based on the ENGAGE AF-TIMI 48 trial.
I. S. Yavelov (2020) conducted a review in Non-valvular atrial fibrillation (n=21,105). Edoxaban vs. Warfarin was evaluated on Stroke (ischemic or hemorrhagic) or systemic embolism (HR 0.79, 95% CI 0.63-0.99, p=<0.001 for noninferiority; 0.02 for superiority). Edoxaban 60/30 mg once daily significantly reduced the risk of stroke or systemic embolism compared to warfarin (HR 0.79, p=0.02 for superiority) in patients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: